Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2022

TCT 158: Pooled analysis of patients undergoing complex PCI with the dual-therapy COMBO stent: The MEGA-COMBO Complex-PCI analysis.

Presenter: Frans Beerkens

September 19, 2022

Presentation TCT 2022

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presenter: Sungsoo Cho

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Presentation TCT 2022

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

Presenter: Johny Nicolas

September 17, 2022

Presentation TCT 2022

TCT 2: Two-Year Outcomes in High Bleeding Risk Patients with Bifurcations after Percutaneous Coronary Intervention and One Month Dual Antiplatelet Therapy

Presenter: Ajay Kirtane

September 17, 2022

Presentation TCT 2022

TCT 15: Dual antiplatelet therapy-based de-escalation in acute coronary syndrome: An individual patient data meta-analysis

Presenter: Jeehoon Kang

September 17, 2022

Presentation TCT 2022

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

Presenter: Giulia Masiero

September 17, 2022

Presentation TCT 2022

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

Presenter: Toshiki Kuno

September 17, 2022

Presentation ESC 2022

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Presenter: John H. Alexander

August 28, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Advertisement

TCT 158: Pooled analysis of patients undergoing complex PCI with the dual-therapy COMBO stent: The MEGA-COMBO Complex-PCI analysis.

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

TCT 2: Two-Year Outcomes in High Bleeding Risk Patients with Bifurcations after Percutaneous Coronary Intervention and One Month Dual Antiplatelet Therapy

TCT 15: Dual antiplatelet therapy-based de-escalation in acute coronary syndrome: An individual patient data meta-analysis

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content